Skip to main content

Table 2 Detailed clinical characteristics and LOH analysis results of the 21 patients included in this study

From: Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis

No.

Sex

Age-ranges

HNSCC

ESCC

This study

Geurts et al., 2005 [16]

Site

Stagea

Site

Stagea

%Discordant LOH

%Concordant LOH

Ratio

Conclusion

Discordant LOHb

Concordant LOH

All discordant LOH

Conclusion

1

M

56–60

oropharynx

T3 N0

M0

middle

T2 N0 M0

95.45

4.55

17.2

SFT/SPM

0

1

5

SPM

2

M

61–65

oropharynx

T1 N0

M0

middle

T2 N1 M0

56.25

43.75

1.3

Undetermined

0

0

0

?

3

M

61–65

oropharynx

T2 N1

M0

middle

T2 N1 M0

100

0

100

SPM

2

0

2

SPM

4

M

36–40

larynx

T3 N3

M0

middle

T1 N0 M0

95.45

4.55

17.2

SFT/SPM

5

0

5

SPM

5

M

51–55

larynx

T1 N0

M0

middle

T2 N1 M0

92.5

7.5

10.9

SFT/SPM

4

2

12

SPM

6

M

61–65

larynx

T1 N0

M0

middle

T2 N0 M0

83.33

16.67

4.7

SFT/SPM

1

2

4

Metas?

7

M

61–65

larynx

T3 N2

M0

middle

T2 N1 M0

100

0

100

SPM

3

0

10

SPM

8

M

76–80

larynx

T3 N0

M0

middle

T2 N0 M0

93.75

6.25

12.9

SFT/SPM

4

1

7

SPM

9

M

41–45

hypopharynx

T3 N2

M0

middle

T3 N1 M0

75

25

2.9

SFT/SPM

3

2

6

SPM

10

M

41–45

hypopharynx

T4 N2

M0

middle

T3 N1 M0

92.59

7.41

11

SFT/SPM

8

0

12

SPM

11

M

51–55

hypopharynx

T2 N2

M0

middle

T2 N1 M0

100

0

100

SPM

0

0

0

?

12

M

56–60

hypopharynx

T2 N0

M0

middle

T2 N0 M0

87.1

12.9

6.3

SFT/SPM

8

0

10

SPM

13

M

61–65

hypopharynx

T3 N0

M0

middle

T3 N2 M0

81.82

18.18

4.3

SFT/SPM

4

1

12

SPM

14

F

66–70

hypopharynx

T3 N2

M0

middle

T2 N0 M0

98.25

1.75

35.7

SFT/SPM

5

1

9

SPM

15

M

81–85

hypopharynx

T1 N3

M0

middle

T2 N1 M0

93.75

6.25

12.9

SFT/SPM

0

0

1

?

16

M

71–75

oropharynx

T3 N1

M0

lower

T2 N0 M0

94.87

5.13

15.5

SFT/SPM

4

0

4

SPM

17

M

46–50

larynx

T1 N0

M0

lower

T2 N1 M0

100

0

100

SPM

7

0

8

SPM

18

M

71–75

larynx

T2 N1

M0

lower

T2 N0 M0

87.5

12.5

6.5

SFT/SPM

9

2

11

SPM

19

M

41–45

hypopharynx

T4 N2

M0

lower

T3 N2 M0

100

0

100

SPM

0

0

2

SPM?

20

M

46–50

hypopharynx

T3 N2

M0

lower

T2 N0 M0

95

5

15.8

SFT/SPM

4

0

7

SPM

21

M

51–55

hypopharynx

T2 N0

M0

lower

T2 N2 M0

100

0

100

SPM

1

0

3

SPM?

  1. LOH, loss of heterozygosity; HNSCC, head and neck squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; SFT, second field tumor; SPM, second primary malignancy;?, inconclusive; SPM?, probably second primary malignancy; Metas?, probably metastasis; M, male; F, female; aAmerican Joint Committee on Cancer (AJCC) stage (7th ed); bDiscordant LOH not explained by tumor progression